Hikma Pharmaceuticals PLC (LON:HIK) Stock “Buy” Rating Reconfirmed at Citigroup; The Target Price is Set to GBX 1475.00; Calithera Biosciences, Inc. (CALA) Had 5 Bullish Analysts

Calithera Biosciences, Inc. (NASDAQ:CALA) Logo

Stock analysts at Citigroup have GBX 1475.00 target on Hikma Pharmaceuticals PLC (LON:HIK). Citigroup’s target would suggest a potential upside of 14.03% from the company’s last stock price. The rating was released in an analyst note on Tuesday morning.

Among 5 analysts covering Calithera Biosciences (NASDAQ:CALA), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Calithera Biosciences had 10 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Buy” rating by Citigroup given on Friday, February 16. The company was initiated on Thursday, January 5 by H.C. Wainwright. Citigroup initiated Calithera Biosciences, Inc. (NASDAQ:CALA) rating on Friday, July 24. Citigroup has “Buy” rating and $11 target. The stock has “Buy” rating by H.C. Wainwright on Monday, June 12. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, March 28 report. JMP Securities maintained it with “Market Outperform” rating and $12 target in Wednesday, March 9 report. The stock of Calithera Biosciences, Inc. (NASDAQ:CALA) earned “Sell” rating by Citigroup on Tuesday, October 25. The stock has “Neutral” rating by Citigroup on Tuesday, January 24. See Calithera Biosciences, Inc. (NASDAQ:CALA) latest ratings:

16/02/2018 Broker: Citigroup Rating: Buy New Target: $14.0 Upgrade

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company has market cap of $220.45 million. The Company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. It currently has negative earnings. The firm has a license agreement with Mars, Inc. to develop and commercialize SymbioscienceÂ’s portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors.

Investors sentiment increased to 2.2 in Q4 2017. Its up 0.98, from 1.22 in 2017Q3. It increased, as 10 investors sold Calithera Biosciences, Inc. shares while 20 reduced holdings. 31 funds opened positions while 35 raised stakes. 24.18 million shares or 4.20% less from 25.24 million shares in 2017Q3 were reported. Ascend Limited Com invested in 0.22% or 693,801 shares. Ameritas Prtn Inc holds 0% of its portfolio in Calithera Biosciences, Inc. (NASDAQ:CALA) for 2,688 shares. Massachusetts-based Adage Capital Prtn Gru Llc has invested 0.03% in Calithera Biosciences, Inc. (NASDAQ:CALA). The Georgia-based Invesco Ltd has invested 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). Bnp Paribas Arbitrage Sa holds 7,164 shares. Secor Capital L P holds 29,533 shares or 0.01% of its portfolio. Alliancebernstein Lp has invested 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). Ubs Asset Mngmt Americas has 0% invested in Calithera Biosciences, Inc. (NASDAQ:CALA). Fmr Limited Co invested in 0% or 680,710 shares. Barclays Public Limited stated it has 0% of its portfolio in Calithera Biosciences, Inc. (NASDAQ:CALA). The Maryland-based Price T Rowe Assocs Md has invested 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). First Allied Advisory Ser reported 0% stake. Legal & General Public Limited owns 7,637 shares for 0% of their portfolio. Wells Fargo Mn invested 0% of its portfolio in Calithera Biosciences, Inc. (NASDAQ:CALA). Trexquant Invest L P stated it has 0.04% in Calithera Biosciences, Inc. (NASDAQ:CALA).

The stock decreased 0.81% or $0.05 during the last trading session, reaching $6.15. About 160,467 shares traded. Calithera Biosciences, Inc. (NASDAQ:CALA) has declined 36.62% since May 1, 2017 and is downtrending. It has underperformed by 48.17% the S&P500.

Hikma Pharmaceuticals PLC develops, makes, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. The company has market cap of 3.12 billion GBP. It operates through three divisions: Branded, Injectables, and Generic. It currently has negative earnings. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system , gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.

The stock increased 0.50% or GBX 6.5 during the last trading session, reaching GBX 1294.5. About 21,308 shares traded. Hikma Pharmaceuticals PLC (LON:HIK) has 0.00% since May 1, 2017 and is . It has underperformed by 11.55% the S&P500.

Among 15 analysts covering Hikma Pharmaceuticals PLC (LON:HIK), 7 have Buy rating, 2 Sell and 6 Hold. Therefore 47% are positive. Hikma Pharmaceuticals PLC has GBX 3400 highest and GBX 800 lowest target. GBX 1405.43’s average target is 8.57% above currents GBX 1294.5 stock price. Hikma Pharmaceuticals PLC had 175 analyst reports since July 29, 2015 according to SRatingsIntel. Numis Securities maintained Hikma Pharmaceuticals PLC (LON:HIK) rating on Friday, August 11. Numis Securities has “Add” rating and GBX 1560 target. The company was maintained on Tuesday, September 15 by Goldman Sachs. The firm has “Neutral” rating given on Thursday, August 24 by Citigroup. The company was maintained on Wednesday, February 10 by J.P. Morgan. The stock has “Overweight” rating by JP Morgan on Thursday, March 17. The firm has “Buy” rating given on Monday, April 4 by Jefferies. The rating was maintained by Stifel Nicolaus on Thursday, November 9 with “Hold”. As per Friday, November 11, the company rating was maintained by HSBC. The stock of Hikma Pharmaceuticals PLC (LON:HIK) earned “Buy” rating by AlphaValue on Thursday, December 24. Jefferies maintained Hikma Pharmaceuticals PLC (LON:HIK) rating on Wednesday, January 17. Jefferies has “Underperform” rating and GBX 895 target.

Calithera Biosciences, Inc. (NASDAQ:CALA) Institutional Positions Chart